Skip to main content
メニュー
Revvity logo
Contact us
JP
Revvity Sites Globally

Select your location.

*e-commerce not available for this region.

australia.webp Australia
austria.webp Austria
belgium.webp Belgium
brazil.webp Brazil *
canada.webp Canada
china.webp China *
denmark.webp Denmark
finland.webp Finland
france.webp France
germany.webp Germany
hong-kong.webp Hong Kong (China) *
india.webp India *
ireland.webp Ireland
italy.webp Italy
japan.webp Japan *
luxembourg.webp Luxembourg
mexico.webp Mexico *
netherlands.webp Netherlands
norway.webp Norway
philippines.webp Philippines *
republic of korea.webp Republic of Korea *
singapore.webp Singapore *
spain.webp Spain
sweden.webp Sweden
switzerland.webp Switzerland
thailand.webp Thailand *
uk.webp United Kingdom
usa.webp United States
Breadcrumb
...
  • ホーム
  • Quantifying the degradation of RBM39 in Neuroblastoma cells treated with molecular glue degraders using HTRF technology
neuroblastoma-molecular-1920x400.jpg
Application Note

Quantifying the degradation of RBM39 in Neuroblastoma cells treated with molecular glue degraders using HTRF technology

See the potential of molecular glue degraders

RNA-binding motif protein 39 is a key factor in tumor-targeted RNA and protein expression that plays an important role in tumorigenesis. It’s important to study the interaction between RBM39 and tumors.

Download this application note, which highlights the use of HTRF immunoassays to evaluate RBM39 degradation in neuroblastoma cancer cells treated with Indilsulam and CeMM1-4 molecular glue degraders.

For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Download Resource

Quantifying the degradation of RBM39 in Neuroblastoma cells treated with molecular glue degraders using HTRF technology

Download Application Note
Revvity Logo

©2025 Revvity - All rights reserved

Revvity is a trademark of Revvity, Inc. All other trademarks are the property of their respective owners.